中文版English

Home | Add to Favorites | Contact Us

Home >> Department >> Innovation Platform >> Beijing Key Laboratory of New Drug Mechanisms and Pharmacological E…

Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study

 

Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study consists of 49 researchers, including 11 full professors and 6 associate professors. The senior staff account for more than 2/3. The study focuses on innovative drug development of cardiovascular and anti-neurodegenerative diseases, anti-infective, anti-tumor and immune-related diseases. Professor Wang Xiaoliang is the laboratory director, and the laboratory director of Academic Committee is held by the Professor Jiang Jiandong.
The main research task is evaluating and developing the innovative drugs of anti-cardiovascular and cerebrovascular diseases, anti-neurodegenerative diseases, anti-tumor and anti-virus by exploring the mechanisms of drugs. We try to build a domestic first-class drug evaluation center for pharmacodynamic, and provide a technical service platform for enterprises of Beijing as well as the rest of the country.
 In the recent five years, the laboratory totally obtained 88 grants, including National Science and Technology Major Special Project on Major New Drug Innovation, 973, 863, major projects of National Natural Science Foundation of China as well as Beijing Natural Science Foundation. Research funds exceed one billion. The laboratory published 285 academic articles, 171 of which were indexed by SCI. The laboratory has also made significant achievements in the drug development. Three new drugs have entered phase II clinical trial, including anti-cerebral ischemia drug (PHPB), anti-renal dysfunction drug (Nicosamide), and anti-rheumatoid arthritis drug (Chlorobenzopiperidone Hydrochloride). FLZ, an anti-Parkinson’ disease drug has applied for clinical trial. A new hyperlipemia regulator- WS070117 is under preclinical trial. Four drug candidates were identified, including the hypoxia inducible factor -1 (HIF-1) inhibitors. Twenty-two patents have been applied for. In addition, we finished nine technical service projects. ‘Cardiovascular, neurodegenerative diseases, non-clinical pharmacodynamic evaluation and application of key technology platform’ won 2012 Chinese Medicine Award.
The key laboratory will integrate the multi-disciplinary, highlight and support the key disciplines, and create the good conditions for scientific research. We will strive to make the key lab a major pharmacological center for basic research and drug development in China, and provide technical support to Beijing and pharmaceutical R&D institutions and enterprises nationally and internationally.